<DOC>
	<DOCNO>NCT01772368</DOCNO>
	<brief_summary>The primary objective study evaluate dose response , efficacy , safety 4 different dos salmeterol Spiromax ( 6.25 , 12.5 , 25 , 50 mcg ) combine fix dose fluticasone propionate ( 100 mcg ) deliver Fluticasone/Salmeterol Spiromax® Inhalation Powder ( FS Spiromax ) administer single dose subject 12 year age old persistent asthma .</brief_summary>
	<brief_title>Dose Ranging Study Salmeterol Component Fluticasone /Salmeterol Spiromax Compared Fluticasone Spiromax Advair Diskus Asthma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Written inform consent/assent General good health Diagnosis asthma define National Institutes Health ( NIH ) A best FEV1 40 % 85 % predict normal value screen visit ( SV ) Subjects need demonstrate ≥ 15 % reversibility FEV1 within 30 minute follow 4 inhalation albuterol inhalation aerosol ( require , spacers permit reversibility test ) SV . Other inclusion criterion apply History lifethreatening asthma define protocol asthma episode require intubation . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve within 2 week prior SV . Any asthma exacerbation require oral corticosteroid within 3 month SV . A subject must hospitalization asthma within 6 month prior SV . Taking longacting βagonists within 2 week SV Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>long-acting beta2-agonist</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>meter dose inhaler</keyword>
	<keyword>inhale corticosteroid</keyword>
</DOC>